This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes
in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer
. Androgen deprivation therapy decreases testosterone and other androgens through medications
or surgical removal of the testicles. Relative to placebo, low- or high-dose oxybutynin may
reduce hot flashes in men receiving androgen deprivation therapy.